Page 2508 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 152 Hematologic Manifestations of Childhood Illness 2237.e3

96. Scott JP, Gerber P, Maryjowski MC, et al: Evidence for intravascular 117. Ramanan AV, Schneider R: Macrophage activation syndrome follow-
coagulation in systemic onset, but not polyarticular, juvenile rheuma- ing initiation of etanercept in a child with systemic onset juvenile
toid arthritis. Arthritis Rheum 28(3):256–261, 1985. rheumatoid arthritis. J Rheumatol 30(2):401–403, 2003.
97. Bloom BJ, Tucker LB, Miller LC, et al: Fibrin d-dimer as a marker 118. Bruck N, Suttorp M, Kabus M, et al: Rapid and sustained remission of
of disease activity in systemic onset juvenile rheumatoid arthritis. systemic juvenile idiopathic arthritis-associated macrophage activation
J Rheumatol 25(8):1620–1625, 1998. syndrome through treatment with anakinra and corticosteroids. J Clin
98. Minoia F, Davi S, Horne A, et al: Clinical features, treatment, and Rheumatol 17(1):23–27, 2011.
outcome of macrophage activation syndrome complicating systemic 119. Melish ME: Kawasaki syndrome. Pediatr Rev 17:153, 1996.
juvenile idiopathic arthritis: a multinational, multicenter study of 362 120. Samada K, Igarashi H, Shiraishi H, et al: Increased serum granulocyte
patients. Arthritis Rheumatol 66(11):3160–3169, 2014. colony-stimulating factor correlates with coronary artery dilatation in
99. Ravelli A, Grom AA, Behrens EM, et al: Macrophage activation Kawasaki disease. Eur J Pediatr 161(10):538–541, 2002.
syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, 121. Abe J, Kotzin BL, Meissner C, et al: Characterization of T cell reper-
genetics, pathophysiology and treatment. Genes Immun 13(4):289–298, toire changes in acute Kawasaki disease. J Exp Med 177(3):791–796,
2012. 1993.
100. Avcin T, Tse SM, Schneider R, et al: Macrophage activation syndrome 122. Kawamori J, Miyake T, Yoshida T: B-cell function in Kawasaki disease
as the presenting manifestation of rheumatic diseases in childhood. J and the effect of high-dose gamma-globulin therapy. Acta Paediatr Jpn
Pediatr 148(5):683–686, 2006. 31(5):537–543, 1989.
101. Ravelli A, De Benedetti F, Viola S, et al: Macrophage activation 123. Rowley AH, Shulman ST, Spike BT, et al: Oligoclonal IgA response in
syndrome in systemic juvenile rheumatoid arthritis successfully treated the vascular wall in acute Kawasaki disease. J Immunol 166(2):1334–
with cyclosporine. J Pediatr 128(2):275–278, 1996. 1343, 2001.
102. Janka GE: Familial and acquired hemophagocytic lymphohistiocytosis. 124. Gupta M, Noel GJ, Schaefer M, et al: Cytokine modulation with
Eur J Pediatr 166(2):95–109, 2007. immune gamma-globulin in peripheral blood of normal children
103. Stephan JL, Kone-Paut I, Galambrun C, et al: Reactive haemophago- and its implications in Kawasaki disease treatment. J Clin Immunol
cytic syndrome in children with inflammatory disorders: a retrospec- 21(3):193–199, 2001.
tive study of 24 patients. Rheumatology (Oxford) 40(11):1285–1292, 125. Nigrovic LE, Nigrovic PA, Harper MB, et al: Extreme thrombocytosis
2001. predicts Kawasaki disease in infants. Clin Pediatr (Phila) 45(5):446–452,
104. Ravelli A, Magni-Manzoni S, Pistorio A, et al: Preliminary diagnostic 2006.
guidelines for macrophage activation syndrome complicating systemic 126. Ishiguro A, Ishikita T, Shimbo T, et al: Elevation of serum thrombo-
juvenile idiopathic arthritis. J Pediatr 146(5):598–604, 2005. poietin precedes thrombocytosis in Kawasaki disease. Thromb Haemost
105. Davi S, Minoia F, Pistorio A, et al: Performance of current guidelines 79(6):1096–1100, 1998.
for diagnosis of macrophage activation syndrome complicating systemic 127. Levin M, Holland PC, Nokes TJ, et al: Platelet immune complex inter-
juvenile idiopathic arthritis. Arthritis Rheumatol 66(10):2871–2880, action in pathogenesis of Kawasaki disease and childhood polyarteritis.
2014. Br Med J (Clin Res Ed) 290(6480):1456–1460, 1985.
106. Janka GE, Schneider EM: Modern management of children with 128. Burns JC, Glode MP, Clarke SH, et al: Coagulopathy and platelet acti-
haemophagocytic lymphohistiocytosis. Br J Haematol 124(1):4–14, vation in Kawasaki syndrome: identification of patients at high risk for
2004. development of coronary artery aneurysms. J Pediatr 105(2):206–211,
107. Bleesing J, Prada A, Siegel DM, et al: The diagnostic significance 1984.
of soluble CD163 and soluble interleukin-2 receptor alpha-chain in 129. Newburger JW, Takahashi M, Burns JC, et al: The treatment of
macrophage activation syndrome and untreated new-onset systemic Kawasaki syndrome with intravenous gamma globulin. N Engl J Med
juvenile idiopathic arthritis. Arthritis Rheum 56(3):965–971, 2007. 315:341, 1986.
108. Grom AA: Macrophage activation syndrome and reactive hemophago- 130. Kato H, Koike S, Yokoyama T: Kawasaki disease: effect of treatment
cytic lymphohistiocytosis: the same entities? Curr Opin Rheumatol on coronary artery involvement. Pediatrics 63(2):175–179, 1979.
15(5):587–590, 2003. 131. Shinohara M, Sone K, Tomomasa T, et al: Corticosteroids in the treat-
109. Grom AA, Villanueva J, Lee S, et al: Natural killer cell dysfunction ment of the acute phase of Kawasaki disease. J Pediatr 135(4):465–469,
in patients with systemic-onset juvenile rheumatoid arthritis and 1999.
macrophage activation syndrome. J Pediatr 142(3):292–296, 2003. 132. Inoue Y, Okada Y, Shinohara M, et al: A multicenter prospective ran-
110. Villanueva J, Lee S, Giannini EH, et al: Natural killer cell dysfunction is domized trial of corticosteroids in primary therapy for Kawasaki disease:
a distinguishing feature of systemic onset juvenile rheumatoid arthritis clinical course and coronary artery outcome. J Pediatr 149(3):336–341,
and macrophage activation syndrome. Arthritis Res Ther 7(1):R30–R37, 2006.
2005. 133. Newburger JW, Takahashi M, Gerber MA, et al: Diagnosis, treatment,
111. Vastert SJ, van Wijk R, D’Urbano LE, et al: Mutations in the perforin and long-term management of Kawasaki disease: a statement for health
gene can be linked to macrophage activation syndrome in patients professionals from the Committee on Rheumatic Fever, Endocarditis,
with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) and Kawasaki Disease, Council on Cardiovascular Disease in the Young,
49(3):441–449, 2010. American Heart Association. Pediatrics 114(6):1708–1733, 2004.
112. Zhang K, Biroschak J, Glass DN, et al: Macrophage activation syndrome 134. Newburger JW, Sleeper LA, McCrindle BW, et al: Randomized trial
in patients with systemic juvenile idiopathic arthritis is associated with of pulsed corticosteroid therapy for primary treatment of Kawasaki
MUNC13-4 polymorphisms. Arthritis Rheum 58(9):2892–2896, 2008. disease. N Engl J Med 356(7):663–675, 2007.
113. Tristano AG, Casanova-Escalona L, Torres A, et al: Macrophage activa- 135. Son MB, Gauvreau K, Burns JC, et al: Infliximab for intravenous
tion syndrome in a patient with systemic onset rheumatoid arthritis: immunoglobulin resistance in Kawasaki disease: a retrospective study.
rescue with intravenous immunoglobulin therapy. J Clin Rheumatol J Pediatr 158(4):644–649, e1, 2011.
9(4):253–258, 2003. 136. Newburger JW, Fulton DR: Kawasaki disease. Curr Treat Options
114. Prahalad S, Bove KE, Dickens D, et al: Etanercept in the treatment Cardiovasc Med 9(2):148–158, 2007.
of macrophage activation syndrome. J Rheumatol 28(9):2120–2124, 137. Dimitriades VR, Brown AG, Gedalia A: Kawasaki disease: pathophysi-
2001. ology, clinical manifestations, and management. Curr Rheumatol Rep
115. Makay B, Yilmaz S, Turkyilmaz Z, et al: Etanercept for therapy-resistant 16(6):423, 2014.
macrophage activation syndrome. Pediatr Blood Cancer 50(2):419–421, 138. Clark JH, Fitzgerald JF: Hemorrhagic complications of Henoch-
2008. Schonlein syndrome. J Pediatr Gastroenterol Nutr 4(2):311–315, 1985.
116. Sellmer A, Stausbøl-Grøn B, Herlin T: Successful use of infliximab in 139. Brendel-Muller K, Hahn A, Schneppenheim R, et al: Laboratory signs
macrophage activation syndrome with severe CNS affection [poster of activated coagulation are common in Henoch-Schonlein purpura.
presentation]. Pediatr Rheumatol Online J 6(Suppl 1):P200, 2008. Pediatr Nephrol 16(12):1084–1088, 2001.